| 2019-09-18 |
1 |
Complaint |
6,340,475 (‘475 patent) 9/16/2016
20 6,635,280 (‘280 patent) …Book patent (the ‘692 patent), as well as two non-Orange Book listed patents
20 (the ‘667 patent and…listed patent(s) and/or the patent is
2 invalid and unenforceable. Simply by listing the patents in the…and U.S. Patent No. 8,329,215 (“the ‘215 patent”)).
21 191. The ‘215 patent, like the ‘667…plaintiffs in the
8 patent lawsuit, Assertio/Santarus, to the defendant in the patent lawsuit, Lupin. Lupin |
External link to document |
| 2020-03-05 |
188 |
Order on Motion to Dismiss |
four relevant patents: U.S. Patent Nos.
21 6,340,475; 6,635,280; 6,488,962… 16 for the patent barrier remains. New brand-drug applicants must list the patents (if any) covering…brand drug, that the relevant patents have expired, or that such patents are invalid or will not be
…infringe the patents
4 because it designed around the patents using a… the patent suit, Lupin would stop challenging the
18 patent, and |
External link to document |
| 2020-04-09 |
226 |
Amended Complaint |
Date Expiration Date
11 6,340,475 (’475 patent) March 29, 1999 January…Book patent (the ’692 patent) as well as two non-
28 Orange Book listed patents (the ’667 patent and…Assertio could not patent the drug itself. Instead, Assertio
13 obtained four patents covering extended-release…Lupin would infringe its patents. But Lupin had designed around Assertio’s patents;
6 indeed, before … would not infringe
7 Assertio’s patents and why the patents were invalid.
8 6. Sun |
External link to document |
| 2020-08-15 |
347 |
Order on Motion to Certify Class |
four relevant patents: U.S. Patent Nos.
10 6,340,475; 6,635,280; 6,488,962…analogous anticompetitive behavior, patent misuse, by holding a patent
…from an alleged reverse-payment settlement of a patent
17 infringement…restating. This case arises from a perversion of the patent and pharmaceutical-
…
4 Patents covering the brand drug can still spoil the fun |
External link to document |
